JGC
ARIA

J. Goldman & Co’s Ariad Pharmaceuticals Inc ARIA Stock Holding History

J. Goldman & Co’s Portfolio ARIA Stock Details ARIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-371,700
Closed -$2.38M – 449
2016
Q1 		$2.38M Buy
+371,700
New +$2.08M 0.15% 168
2014
Q3 		– Sell
-205,000
Closed -$1.31M – 376
2014
Q2 		$1.31M Buy
+205,000
New +$1.41M 0.1% 173

Other funds holding ARIA

PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

J. Goldman & Co's ARIA Position: Q2 2016 in Review

J. Goldman & Co sold out of Ariad Pharmaceuticals Inc (ARIA) in Q2 2016, closing a stake of 371,700 shares — an estimated $2.38M sold.

J. Goldman & Co first reported a position in ARIA in Q2 2014 and held it in 2 quarters. The position peaked at $2.38M in Q1 2016. 182 funds tracked by Wall St. Rank hold ARIA as of Q2 2016.

  • J. Goldman & Co reported no remaining Ariad Pharmaceuticals Inc position as of Q2 2016 after selling out during the quarter.
  • J. Goldman & Co sold 371,700 Ariad Pharmaceuticals Inc shares in Q2 2016, an estimated $2.38M.
  • J. Goldman & Co first reported a position in Ariad Pharmaceuticals Inc in Q2 2014 and held it in 2 quarters.
  • J. Goldman & Co's Ariad Pharmaceuticals Inc position peaked at $2.38M in Q1 2016.
  • 182 funds tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q2 2016.

Based on J. Goldman & Co's 13F filing for Q2 2016, filed 15 Aug 2016.